SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the Company will present nine abstracts in rare kidney disease at the World Congress of Nephrology (WCN) in Buenos Aires, Argentina, on April 13-16, 2024, and the American Nephrology Nurses Association (ANNA) National Symposium in Orlando, Florida, on April 14-17, 2024.

2024年4月3日，圣地亚哥（环球通讯社）——Travere Therapeutics，Inc.（纳斯达克：TVTX）今天宣布，该公司将于2024年4月13日至16日在阿根廷布宜诺斯艾利斯举行的世界肾脏病大会（WCN）和2024年4月14日至17日在佛罗里达州奥兰多举行的美国肾脏病护士协会（ANNA）全国研讨会上发表9篇罕见肾脏病摘要。

At WCN, the Company will present subgroup analyses of the Phase 3 PROTECT Study of FILSPARI® (sparsentan) in IgA nephropathy (IgAN) showing the treatment effect across participants with different levels of baseline proteinuria. Encore presentations will include preliminary findings from the SPARTAN Study supportive of FILSPARI as a first-line treatment for patients with IgAN, as well as the early clinical experience from the PROTECT open-label extension regarding the addition of sodium-glucose cotransporter-2 inhibitors (SGLT2i) to ongoing FILSPARI treatment in patients with IgAN.

在WCN上，该公司将对IgA肾病（IgAN）中FILSPARI®（sparsentan）的3期PROTECT研究进行亚组分析，显示不同基线蛋白尿水平参与者的治疗效果。Encore演示将包括SPARTAN研究的初步结果，支持FILSPARI作为IgAN患者的一线治疗，以及PROTECT开放标签扩展的早期临床经验，即在IgAN患者的持续FILSPARI治疗中添加钠-葡萄糖协同转运蛋白-2抑制剂（SGLT2i）。

At ANNA, the Company will present additional insights from the HONUS trial, including health-related quality of life (HRQoL) data and the humanistic burden experienced by patients with IgAN and focal segmental glomerulosclerosis (FSGS). “The data we are presenting at WCN and ANNA reinforce the wealth of evidence supporting FILSPARI’s profile to become an effective foundational treatment replacing RAAS inhibition, with the potential to reduce the lifetime risk of kidney failure for patients with IgAN,” said Jula Inrig, M.D., chief medical officer of Travere Therapeutics.

在ANNA，该公司将介绍HONUS试验的其他见解，包括与健康相关的生活质量（HRQoL）数据以及IgAN和局灶性节段性肾小球硬化症（FSGS）患者所经历的人文负担。Travere Therapeutics首席医疗官Jula Inrig医学博士说：“我们在WCN和ANNA上提供的数据加强了支持FILSPARI概况的大量证据，成为替代RAAS抑制的有效基础治疗方法，有可能降低IgAN患者终生肾衰竭的风险。”。

“We are also looking forward to presenting data that address broader aspects of disease management, building upon Travere’s holistic approach to improving patient outcomes in RKD.” WCN Late Breaking Abstract Sparsentan vs Irbesartan in Patients with Im.

“我们也期待着提供数据，解决疾病管理的更广泛方面，以Travere的整体方法为基础，改善RKD患者的预后。”WCN迟发性抽象斯巴森坦与厄贝沙坦治疗Im患者。